Janssen COVID-19 Vaccine is an adenovirus-based vaccine used for active immunization against COVID-19 caused by SARS-CoV-2 infection. The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein.
- Mechanism
- Curator reviewed · 1 reference
The Janssen COVID-19 Vaccine comprises a recombinant, replication-incompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 Spike (S) protein in a stabilized conformation. Immunization with the vaccine results in the expression of SARS-CoV-2 spike proteins in the recipient, which stimulates antibody formation and cellular immune responses directed against the S antigen and ultimately conferring immunological protection to the SARS-CoV-2 virus.
- Primary indication
- Janssen COVID-19 Vaccine is indicated for active immunization for the prevention of coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 virus in individuals 18 years of age and older.Curator reviewed · 2 structured indications
- First approval
- Canada, 2022
- Also known as
- AD26.COV2.S [RECOMBINANT] · Ad26COVS1 · Adenovirus type 26 encoding SARS-COV-2 spike glycoprotein
- Code names
- Ad26.COV2.S · JNJ-78436735
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Janssen COVID-19 Vaccine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account